美洲大蠊i型溶菌酶的原核表达及多克隆抗体制备

旨在获得美洲大蠊i型溶菌酶Pa I的原核表达蛋白,并制备鼠抗Pa I多克隆抗体。PCR扩增Pa I成熟肽编码序列,构建原核表达载体p ET28a-Pa I,诱导表达、纯化Pa I-His融合蛋白,免疫Balb/c小鼠,间接ELISA法检测抗血清效价,Western blotting检测多克隆抗体的特异性。结果显示,Pa I成熟肽部分的编码序列长414 bp,由137个氨基酸组成。构建的原核表达载体p ET28a-Pa I在大肠杆菌Rosetta(DE3)中成功表达,SDS-PAGE检测显示纯化的Pa I-His融合蛋白的大小约为18 k D,间接ELISA和Western blotting分析表明免疫小鼠产生的抗血清具有较高的效价和较强的特异性。美洲大蠊溶菌酶Pa I成功实现原核表达,并获得了高效价特异性多克隆抗体。     

斑点叉尾鮰NK-lysin基因的cDNA克隆及融合表达质粒构建

以斑点叉尾鮰(Ictalurus punctatus)NK-lysin-type1的成熟肽为研究目标,首先通过RT-PCR和巢式PCR从斑点叉尾鮰的鳃中克隆到编码NK-lysin成熟肽的基因,该基因编码由92个氨基酸残基组成的成熟肽;6个高度保守的半胱氨酸残基位于成熟肽内,它们被推测与NK-lysin的抗菌活性有关。为了进一步构建原核表达系统用于成熟肽的表达,pET-32a(+)被选择作为融合表达质粒,该质粒含有1个trxA融合头基因,与目的片段mNK-lysin连接后形成融合基因trxA-mNK-lysin,进而有助于在工程菌E.coliBL21(DE3)中的可溶性融合表达。通过PCR、EcoR I和HindⅢ双酶切处理以及DNA测序鉴定,证明pET-32a-mNK-lysin重组融合表达质粒已经被成功构建;将其转化至工程菌E.coliBL21(DE3)后的测序结果表明该重组质粒未发生任何DNA变异。     

新型冠状病毒S蛋白RBD肽段的原核表达与纯化

目的:利用原核系统对新型冠状病毒S蛋白的受体结合域(RBD)肽段进行克隆、表达和纯化,制备高纯度的RBD肽。方法:在RBD肽段N端加入肠激酶位点序列(DDDDK),对应的核酸序列参照原核系统表达偏好进行全基因合成,构建pET-DsbC-RBD融合表达载体,通过原核表达和亲和纯化获得DsbC-RBD融合蛋白,用肠激酶对融合蛋白进行酶切和二次亲和纯化,获得高纯度新冠病毒S蛋白RBD肽。结果:构建了pET-DsbC-RBD表达载体,融合蛋白DsbC-RBD在大肠杆菌中实现了高效表达,经亲和层析纯化,重组融合蛋白DsbC-RBD相对分子质量为58×103,纯度约90%。用肠激酶对融合蛋白进行酶切,酶切效率近100%,通过二次亲和纯化获得了RBD肽,相对分子质量为25×103,纯度92%以上。结论:利用原核表达系统获得可溶性DsbC-RBD融合蛋白,采用亲和纯化和肠激酶酶切联用的方法制备获得高纯度的新冠病毒S蛋白RBD肽,为后续抗体制备和抗病毒药物筛选奠定了基础。     

番茄内质网ω-3脂肪酸去饱和酶基因原核表达载体的构建与鉴定

通过RT-PCR的方法从番茄叶片克隆到内质网ω-3脂肪酸去饱和酶(LeFAD3)基因的部分编码区,该片段cDNA为309 bp,将其克隆到pET-30a(+)载体中,酶切位点分别是BamH I和Sac I,构建了原核表达载体pET-LeFAD3,并在大肠杆菌BL21中表达融合蛋白,经IPTG诱导蛋白表达,提取蛋白并采用SDS-PAGE和蛋白质免疫印迹法检测目的蛋白的表达情况.酶切鉴定结果表明,LeFAD3基因原核表达载体构建成功,目的蛋白成功表达.     

可溶性HLA-A*0203-BSP原核表达载体的构建及其在大肠杆菌中的高效表达

目的：构建HLA-A*0203重链胞外域羧基端融合生物素化酶BirA底物肽(BSP)的融合蛋白（HLA-A*0203-BSP）的原核表达载体并在大肠杆菌中进行表达。方法：以RT-PCR方法从HLA-A2+ 供者外周血单个核细胞(PBMC)中克隆HLA-A*0203重链基因的cDNA并测序鉴定,然后以PCR方法构建HLA-A*0203-BSP的原核表达载体,在大肠杆菌BL21(DE3)菌株中诱导表达并以免疫印迹鉴定。结果：DNA测序显示,从3名HLA-A2+ 供者PBMC中克隆的cDNA中,只有从供者2获得编码HLA-A*0203重链基因的cDNA。将编码重链胞外域1-276的序列和编码BSP的序列融合,构建HLA-A*0203-BSP融合蛋白的原核表达载体并经测序验证。该融合蛋白在BL21(ED3)中获得高效表达,约占菌体总蛋白的30％;产物相对分子质量约为34 kD,与理论大小一致。Western印迹分析显示融合蛋白完全存在于包涵体中。结论：成功克隆HLA-A*0203重链基因的cDNA,构建HLA-A*0203-BSP融合蛋白的原核表达载体,并在大肠杆菌中获得高效表达,为制备HLA-A*0203四聚体打下基础。     

骆驼蓬脂转移蛋白基因克隆、表达及体外抗癌活性分析

[目的]构建骆驼蓬脂转移蛋白(Ph LTP)原核表达载体,并研究表达产物的体外抗癌活性。[方法]采用RT-PCR法从骆驼蓬(Peganum harmala)叶中扩增Ph LTP基因,将其成熟肽片段克隆至p ET-30a载体上,构建表达载体p ET-30a-Ph LTP,将重组质粒转化E.coli BL21进行原核表达,通过镍柱纯化获得重组骆驼蓬脂转移蛋白(r Ph LTP),经SDS-PAGE和Western blot分析鉴定,用MTT法检测其体外抗癌活性。[结果]成功构建骆驼蓬脂转移蛋白c DNA表达载体p ET-30a-Ph LTP,其在E.coli中以可溶性融合蛋白形式表达,分子量约为18 k Da。经镍柱纯化后重组蛋白r Ph LTP能够显著抑制宫颈癌He La、黑色素瘤B16和食管癌Eca-109细胞的生长,IC50值分别为16.76±1.23、38.92±2.16和9.01±1.01μg/m L。[结论]克隆了骆驼蓬脂转移蛋白基因并在原核表达系统中成功表达,r Ph LTP所显示的显著抗癌活性预示其具有临床应用的潜能。     

Tamdy病毒糖蛋白基因的重组表达及抗体制备

原核表达Tamdy病毒（Tamdy virus,TAMV）糖蛋白Gn和Gc,分别制备兔抗融合蛋白Gn和Gc多克隆抗体。利用RT-PCR扩增Gn和Gc基因片段,分别构建原核表达质粒pET-28a-Gn和pET-32a-Gc,并在E.coli BL21(DE3)中诱导表达,镍柱亲和层析纯化融合蛋白Gn和Gc之后,以皮下注射方式分别免疫新西兰兔,制备兔抗融合蛋白Gn和Gc多克隆抗体。经Western Blotting和间接免疫荧光（IFA）鉴定多克隆抗体抗原识别能力,ELISA法测定抗体效价。结果显示,pET-28a-Gn、pET-32a-Gc原核表达质粒构建正确,融合蛋白Gn和Gc大小分别约为45 kD、74 kD,制备的兔抗融合蛋白Gn和Gc多克隆抗体能够分别识别原核表达的融合蛋白Gn和Gc和真核表达产物,效价分别为1∶409 600、1∶204 800。制备的多克隆抗体效价高,能够特异性识别原核系统和真核系统表达的TAMV糖蛋白,为TAMV的流行学分析提供基础。     

融合基因Mdc-hly的构建及原核表达

构建家蝇天蚕素-人溶菌酶(Mdc-hly)融合基因,实现Mdc-hly基因在大肠杆菌中的表达。通过RT-PCR分别扩增出家蝇天蚕素和人溶菌酶的成熟肽基因序列,再利用Gene-SOEing技术构建融合基因,将融合基因克隆至pET32a表达载体,转化E.coli BL21(DE3),经IPTG诱导得到高效表达,融合蛋白分子量约为38kD。Western blotting杂交证实了表达蛋白的抗原活性。成功构建了融合其因并进行了原核表达,为进一步的生物活性研究打下基础。     

拟穴青蟹抗菌肽hyastatin基因原核表达条件的优化

旨在优化拟穴青蟹抗菌肽hyastatin基因原核表达条件。克隆拟穴青蟹抗菌肽hyastatin基因成熟肽片段,与p ET-28a表达载体连接后,转入到大肠杆菌BL21(DE3)中,通过优化条件进行诱导表达。结果显示,在异丙基-β-D-硫代半乳糖苷(IPTG)浓度0.2 mmol/L、37℃条件下培养4 h后表达量最大,分子大小与预期值相符。融合蛋白主要以包涵体形式高效表达,通过His Trap HP柱子使其得到进一步纯化。Western blot分析表明,该融合蛋白可与鼠抗His-tag单克隆抗体发生特异性结合。说明通过优化表达条件,获得拟穴青蟹抗菌肽hyastatin基因原核表达表达产物。     

雪莲类PEBP基因在大肠杆菌中的表达及鉴定

本实验旨在构建雪莲类PEBP基因原核表达载体,在大肠杆菌中表达并纯化类PEBP基因所编码的蛋白,为进一步研究奠定基础.将雪莲类PEBP基因开放阅读框序列克隆到原核表达载体pET30( )上,转化感受态表达菌株BL21(DE3),低浓度IPTG低温诱导融合蛋白的表达,纯化产物,Western blotting鉴定目的蛋白.IFTG低诱导PEBP,经SDS-PAGE分析,其相对分子量约为28 kD,与预期相符,表达量约占菌体蛋白的26.8%,并且通过亲和层析纯化了重组融合蛋白,Western blotting鉴定为阳性.成功构建了原核表达载体pET-PEBP,获得了高效表达产物,并为进一步研究雪莲类PEBP基因的抗冻功能打下基础.     

斜纹夜蛾Cecropin D成熟肽的原核表达及活性检测

采用RT-PCR方法从斜纹夜蛾Spodoptera litura脂肪体组织中扩增得到了Cecropin D成熟肽基因序列,分析发现Cecropin D成熟肽与斜纹夜蛾Cecropin B之间存在2个氨基酸残基的差异。将获得的基因序列连接入原核表达载体pGEX-4T-1,并在原核细胞中实现了该蛋白的融合表达。SDS-PAGE结果表明,诱导后的宿主菌比未诱导菌中多出了一条融合蛋白表达带,诱导后1 h就可以检测到该蛋白,从诱导后1 h到5 h该蛋白在表达量上没有明显的差异。生长曲线显示在IPTG诱导后宿主菌的生长受到明显的抑制,纯化后的蛋白对细菌具有一定的抑制作用。     

家蚕抗菌肽CD高效表达及其抗BmNPV感染作用

通过大肠杆菌JM109诱导家蚕,提取其脂肪体总mRNA后,通过RT-PCR得到cDNA,根据GenBank上家蚕抗菌肽CecropinD的cDNA序列,设计并合成引物,然后PCR扩增得到CecropinD肽基因并克隆到pGEM-T载体中,经过EcoRΙ和XhoI酶切,连接并将CecropinD肽基因插入pET32a表达载体中。用重组质粒pET32a-ecropinD转化大肠杆菌BL21(DE3),在IPTG诱导下,融合蛋白Trx-CecropinD以可溶形式得到高效表达,经SDS-PAGE检测显示分子量为23kDa与预期大小相符,表达量约为总蛋白的30%。融合蛋白经Ni2 柱纯化后通过肠激酶切割后释放为Trx(18kDa)和CecropinD(5kDa),最后通过超滤管分离得到重组抗菌肽。通过抑菌实验测得重组CecropinD对于革兰氏阴性及阳性菌均有抑菌活性。并将重组CecropinD与家蚕病毒BmNPV作用混合4h后,一起投喂家蚕,发现病毒感染力有明显降低,说明其有抗病毒感染作用。     

凋亡抑制因子Survivin在大肠杆菌TB1中的表达纯化及鉴定

 本文旨在克隆凋亡抑制因子Survivin基因,并在大肠杆菌中进行可溶性表达与初步纯化. 采用RT-PCR法,扩增人凋亡抑制因子survivin cDNA,并克隆入原核表达载体pMAL p2X中,转化TB1大肠杆菌感受态细胞.经0.3 mmol/L IPTG诱导2 h后,收集菌体蛋白,进行SDS-PAGE、ELISA及Western 印迹鉴定. 实验获得凋亡抑制因子survivin编码区cDNA,以构建的原核表达载体pMAL-p2X survivin转化菌株后,可表达凋亡抑制因子survivin和麦芽糖结合蛋白(MBP)的融合蛋白,相对分子质量(Mr) 为58 000.并成功利用Factor Xa将融合蛋白裂解开.ELISA和Western 印迹表明,融合蛋白能与抗凋亡抑制因子survivin单克隆抗体特异性结合.获得的凋亡抑制因子survivin全长cDNA可在大肠杆菌TB1中以MBP survivin融合蛋白的形式表达,成功地将survivin目的蛋白和MBP蛋白分离,为深入研究survivin的结构和功能奠定了基础.     

鸡β-防御素7在大肠杆菌中的表达及活性分析

【目的】根据鸡β-防御素7(Gal-7)的成熟肽基因序列合成基因,构建表达Gal-7的大肠杆菌工程菌,研究重组鸡防御素Gal-7成熟肽的体外生物活性。【方法】将合成的gal-7基因克隆到大肠杆菌表达载体pGEX-6p-1中,得到重组质粒pGEX-6p-gal7,转化大肠杆菌BL21(DE3),经IPTG诱导表达得到含GST标签的融合蛋白GST-Gal7;之后用Prescission蛋白酶将GST标签切除,并对成熟肽进行质谱分析;再利用琼脂打孔扩散法检测Gal-7成熟肽的体外抑菌活性,用2倍稀释法测定对指示菌的最低抑菌浓度。【结果】成功构建Gal-7大肠杆菌异源表达工程菌,表达纯化的重组Gal-7成熟肽质谱鉴定分子量为5 516 Da,其对黄色微球菌(NCIB 8166)、金黄色葡萄球菌(ATCC 25923)、粪肠球菌(ATCC 29212)、大肠杆菌(CMCC 44102)均有抑菌活性,最低抑菌浓度分别为16.875、67.5、67.5、135 mg/L。【结论】获得表达鸡Gal-7成熟肽的大肠杆菌工程菌,并且切除GST标签的Gal-7成熟肽具有生物活性。     

High-level production of bioactive human beta-defensin-4 in Escherichia coli by soluble fusion expression

Human beta-defensin-4 (hBD4) is a cationic 50-amino acid antimicrobial peptide with three conserved cysteine disulfide bonds. It exhibits a broad antimicrobial spectrum. This study describes the synthesis of hBD4 gene, the heterologous fusion expression of the peptide in Escherichia coli, and the bioactive assay of released hBD4. A PCR-based gene SOEing (splicing by overlap extension) synthesis method was used in the synthesis of the hBD4 gene with optimized codons. By constructing the expression plasmid (pET32-smhBD4), high concentration of soluble hBD4 fusion protein (1.9 g/l) can be obtained in E. coli. Further optimization studies showed that the expression system was very efficient to produce soluble target protein, and the solubility of the target protein could attain more than 99% even when the culture temperature was as high as 37°C. The highest productivity (2.68 g/l) of the hBD4 fusion protein was achieved by cultivating the E. coli (pET32-smhBD4) in MBL medium at 34°C, inducing the culture at the mid-exponential phase with 0.4-mM isopropyl β-d-galactopyranoside (IPTG), and collecting the broth after 6-h expression. The soluble target protein accounted for 64.6% of the total soluble proteins, and the mature hBD4 expression level was stoichiometrically estimated to be 0.689 g/l. This fusion protein was then purified and cleaved to get the mature hBD4 peptide that showed antimicrobial activity against E. coli and Pseudomonas aeruginosa.     

Overproduction of biologically-active human nerve growth factor in Escherichia coli.

A gene coding for human nerve growth factor (hNGF) was constructed for expression under control of the trp promoter in E. coli. The plasmid pTRSNGF contained a synthetic hNGF gene fused, in frame, to the region encoding the beta-lactamase signal peptide. The plasmid pTRLNGF contained the same coding sequence as hNGF attached downstream from the N-terminal fragment of the trp L gene. E. coli cells harboring pTRSNGF produced an amount of hNGF constituting 4% of the total cellular protein, and removed the beta-lactamase signal peptide. The mature protein hNGF was biologically active in the PC12h bioassay for neurite outgrowth. This biological activity was comparable to that of authentic mouse NGF. E. coli cells harboring pTRLNGF produced an amount of fusion protein hNGF constituting 25% of the total cellular protein. Although the fusion protein hNGF formed inclusion bodies in cells, dissolved fusion protein hNGF was active in neurite outgrowth from PC12h cells.     

Expression, purification, and characterization of a novel methyl parathion hydrolase

The mpd gene coding for a novel methyl parathion hydrolase (MPH) was previously reported and its putative open reading frame was also identified. To further confirm its coding region, the intact region encoding MPH was obtained by PCR and expressed in Escherichia coli as a hexa-His C-terminal fusion protein. The fusion protein was purified to homogeneity by metal-affinity chromatography. The enzyme activity and zymogram assay showed that the fusion protein was functional in degrading methyl parathion. The amino terminal sequencing of the purified recombinant MPH indicated that a signal peptide of the first 35 amino acids was cleaved from its precursor to form active MPH. A rat polyclonal antiserum was raised against the purified mature fusion protein. The results of Western blot and zymogram demonstrated that mature MPH in native Plesiomonas sp. strain M6 was also processed from its precursor by cleavage of a putative signal peptide at the amino terminus. The production of active MPH in E. coli was greatly improved after the coding region for the signal peptide was deleted. HPLC gel filtration of the purified mature recombinant MPH revealed that the MPH was a monomer.